Powered by

-Mirati Therapeutics Reports Second Quarter 2019 Financial Results

Aug 06, 2019 - ENP Newswire
Board and Executive Moves-Financial Results

SAN DIEGO - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019.

Initiated the Phase 3 randomized clinical trial, evaluating the combination of sitravatinib and nivolumab versus single-agent docetaxel, in second line patients with advanced non-squamous non-small cell lung cancer (NSCLC), following treatment with a first line, platinum-based regimen and a checkpoint inhibitor.

Second Quarter Highlight...